Total pharma industry deals for July 2019 worth $4.57bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 95.6% over the previous month and a drop of 82.3% when compared with the last 12-month average of $25.81bn.

In terms of number of deals, the sector saw a drop of 4.4% over the last 12-month average with 130 deals against the average of 136 deals.

In value terms, Europe led the activity with deals worth $2.63bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharma industry deals in July 2019: Top deals

The top five pharma deals accounted for 49.1% of the overall value during July 2019.

The combined value of the top five pharma deals stood at $2.25bn, against the overall value of $4.57bn recorded for the month.

The top five pharma industry deals of July 2019 tracked by GlobalData were:

1) Permira Advisers’ $748.82m private equity deal with Quotient Sciences

2) The $557.13m acquisition of Breath Therapeutics by ZambonSpA

3) Boehringer Ingelheim International‘s $366.22m acquisition of Amal Therapeutics

4) The $325m venture financing of BioNTech by BVCF Management, Fidelity Management & ResearchLLC, Jebsen Capital, Mirae Asset Financial Group, Platinum Asset Management, Redmile Group, Steam Athena Capital, Strungmann Family and Invus Group

5) Fujifilm Cellular Dynamics, Leaps by Bayer and Versant Venture Management’s venture financing of Century Therapeutics for $250m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.